Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 9/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.56 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4921992 | 0.99 | CHRM2 (0.55) | CHRM3CHRM2CHRM1ACHEKEAP1 | |
| SCHEMBL4921985 | 0.86 | ALDH1A1 (0.57) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL4918559 | 0.86 | CHRM3 (0.56) | CHRM3ACHEBCHE | |
| SCHEMBL4143564 | 0.84 | CHRM3 (0.52) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL4620525 | 0.84 | CHRM3 (0.52) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL3226713 | 0.84 | CHRM3 (0.51) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL4619567 | 0.84 | CHRM3 (0.51) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL4924657 | 0.80 | CHRM3 (0.47) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL9477536 | 0.79 | ACHE (0.69) | ACHEBCHE | |
| SCHEMBL4891854 | 0.78 | CHRM3 (0.60) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262075-A1 | Pyrrolidine Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-10-23 | — | — | US | claimed |
| US-20080262075-A1 | Pyrrolidine Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-10-23 | — | — | US | disclosed |
| EP-1781607-A2 | PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018708-A2 | PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262075-A1 | Pyrrolidine Derivatives as Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | CHRM3 1/4885CHRM2 2/4885CHRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.